Rnai Therapeutics

1 article

Abstract representation of AI algorithms analyzing a DNA helix, symbolizing the partnership between Alnylam and Inceptive Nucleics for RNAi therapeutic development.

Alnylam partners with Inceptive Nucleics for AI-driven RNAi therapeutics

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, just committed $30 million upfront and up to $2 billion to Silicon Valley biotech startup Inceptive Nucleics.

Marcus Cole·June 4, 2026